NCT01323829

Brief Summary

This is a prospective, pilot, longitudinal study to evaluate the use of EMG guidance for Botox A injection for chronic pelvic pain and HTPFD. The objective of this study is to determine the efficacy of injecting botulinum toxin type A into pelvic floor muscles that are high tone. Patients who have been diagnosed with high tone pelvic floor muscle dysfunction and have failed other treatments will be eligible to participate in this study. Study related procedures will include perineometry readings. Patients will be required to complete 7 questionnaires for this study. These include visual analog scale (scale from 0-10) for pain (VAS), the O'Leary-Sant urinary symptoms and problem questionnaires (ICSI/ICPI), Pelvic Floor Distress Inventory 20 (PFDI-20), the Female Sexual Distress Scale (FSDS), Global Response Assessment Scale and the SF-12 quality of life scale. The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections. This is a prospective, pilot, longitudinal study to evaluate the effect of Botox A injection for chronic pelvic pain and HTPFD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2010

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

March 24, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 28, 2011

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2013

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

May 5, 2014

Status Verified

May 1, 2014

Enrollment Period

2.7 years

First QC Date

March 24, 2011

Last Update Submit

May 2, 2014

Conditions

Keywords

High Tone Pelvic Floor DysfunctionBotulinum toxin type AEMG

Outcome Measures

Primary Outcomes (1)

  • To evaluate the use of EMG guidance for Botox A injection for chronic pelvic pain and HTPFD.

    6 months

Interventions

The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.

Eligibility Criteria

Age18 Years - 79 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participant must be diagnosed with High Tone Pelvic Floor Dysfunction(HTPMFD).
  • Participant must have tried and failed at least one other conventional mode of therapy for HTPMFD.
  • Participant must be a female at least 18 years of age.
  • Participant must give written informed consent to participate in this study.
  • Participant must be able to make decisions for herself.
  • Participant must not be undergoing another procedure at the time of BTX A injection.

You may not qualify if:

  • Participant is male.
  • Patient has a history of past BTX A use
  • Patient has had pelvic organ prolapse repair
  • Participant is pregnant or intends to get pregnant during the study period or is breastfeeding.
  • Participant is unwilling or unable (because of long distance from office) to follow-up.
  • Participant has a neuro-modulator device implanted.
  • Participant has a known bleeding disorder or is on anticoagulation.
  • Participant has a known hypersensitivity to BTX A.
  • Participant has a pre-existing neuromuscular disorder such as amytrophic lateral sclerosis, motor neuropathy, myasthenia gravis or Lambert-Eaton syndrome.
  • Participant with skin infection at the perineum at the site of injection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pelvic and Sexual Health Institute

Philadelphia, Pennsylvania, 19107, United States

Location

Study Officials

  • Kristene E Whitmore, MD

    Pelvic and Sexual Health Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Director

Study Record Dates

First Submitted

March 24, 2011

First Posted

March 28, 2011

Study Start

November 1, 2010

Primary Completion

July 1, 2013

Study Completion

December 1, 2013

Last Updated

May 5, 2014

Record last verified: 2014-05

Locations